Skip to content
DraconiticResearch
Search Sources API
194,164 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY 4.0PLOS Medicine

Pancreatic cancer: The RAS paradigm shift

  • Samuel P. Soff1,2
  • Eileen M. O’Reilly1,2
  1. 1Department of Medicine, Weill Cornell Medicine, New York, New York, United States of America
  2. 2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
Read full textPDFDOICite

Abstract

Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. Recent advances in RAS targeting with small molecules are redefining therapeutic paradigms.

Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. In this Perspective, Samuel Soff and Eileen O'Reilly discuss recent breakthroughs and clinical trial results of RAS-targeting small molecule inhibitors, as well as the challenges of treatment resistance.

Related

  1. Editorial: The insights of multi-omics into the microenvironment after tumor metastasis: a paradigm shift in molecular targeting modeling and immunotherapy for advanced cancer patients, volume II
    Mengyan Xie, Hong Chang, Xue Zhao +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  2. Repeat breast-conserving surgery for ipsilateral breast tumour recurrence: towards a paradigm shift—a narrative review
    Gland SurgeryPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. The Endophthalmitis Paradigm Shift: Lessons From 25 Years of Changing Ophthalmic Practice
    Catherine Creuzot-Garcher
    Journal of Clinical & Experimental OphthalmologyPeer-reviewedLicence not statedFull textGeneral biologyGeneral medicineHAL
  4. Patient experience of postoperative pain: a paradigm shift to a holistic approach
    Dan Benhamou, Patrice Forget
    British Journal of AnaesthesiaPeer-reviewedLicence not stated3 citedGeneral biologyPharmacology & toxicologyHAL
  5. Repurposing, redefining, and reimagining: A paradigm shift towards person-driven neuroscience in the digital age
    Becky Inkster, Mark Sheppard
    PsyArXivPreprintAll rights reservedFull textNeurosciencePsychiatry & mental healthOSF

Cite

BibTeXRIS
BibTeX
@article{soff2026pancreatic,
  title = {{Pancreatic cancer: The RAS paradigm shift}},
  author = {Samuel P. Soff and Eileen M. O’Reilly},
  journal = {PLOS Medicine},
  year = {2026},
  month = oct,
  doi = {10.1371/journal.pmed.1005283},
  url = {https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005283},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Pancreatic cancer: The RAS paradigm shift
AU  - Samuel P. Soff
AU  - Eileen M. O’Reilly
PY  - 2026
DA  - 2026/10/29
JO  - PLOS Medicine
DO  - 10.1371/journal.pmed.1005283
UR  - https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005283
AB  - Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. Recent advances in RAS targeting with small molecules are redefining therapeutic paradigms.  Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. In this Perspective, Samuel Soff and Eileen O'Reilly discuss recent breakthroughs and clinical trial results of RAS-targeting small molecule inhibitors, as well as the challenges of treatment resistance.
SN  - 1549-1676
SN  - 1549-1277
ER  -